Navigation Links
NAMS issues new guidance on vulvovaginal atrophy
Date:8/28/2013

CLEVELAND, Ohio (August 29, 2013)Symptoms of vulvovaginal atrophy (VVA), such as lack of lubrication, irritated tissues, painful urination, and pain with intercourse, affect as many as 45% of women after menopause. That's according to The North American Menopause Society (NAMS), which today published new guidance for diagnosing and treating VVA. The Society's Position Statement "Management of Vulvovaginal Atrophy" appears in the September issue of Menopause.

"The symptoms of VVA can significantly impair women's quality of life and relationships, yet few women whose lives are affected get help. This new Position Statement gives clinicians the information they need to address these problems," says Margery Gass, MD, the Society's Executive Director.

The Position Statement explains that bothersome symptoms can be treated successfully, and many treatments are available, ranging from over-the-counter products to prescription hormonal and nonhormonal products. Which therapy to use depends on how severe the symptoms are, whether the therapy is safe and effective for the individual woman, and what she prefers.

Simple vaginal lubricants and moisturizers along with regular intercourse (or use of vaginal dilators) can be effective and are considered first-line therapy by NAMS. When these are not effective, estrogen, either applied locally or as part of systemic hormone therapy, remains the therapeutic standard. A nonhormonal option, the selective estrogen-receptor modulator ospemifene, was recently approved for moderate to severe painful intercourse.

For hormonal therapy, low-dose vaginal estrogen is the preferred approach when VVA symptoms are the only bothersome menopausal symptoms a woman has. Generally, women who use a vaginal estrogen do not need to take a progestogen to protect the uterus if they have not had a hysterectomy.

For a woman who is a survivor of breast or endometrial cancer, the choice of treatment depends o
'/>"/>

Contact: Eileen Petridis
epetridis@fallscommunications.com
216-696-0229
The North American Menopause Society (NAMS)
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Online USA Doctors Announces a New Male Treatment Program For Sensitive Male Health Issues
2. Transvaginal Mesh Multidistrict Litigation Update: Court Issues New Pretrial Order that Moves Ethicon Inc.’s Discovery Forward, Notes Parker Waichman
3. Research examines parents use of bibliotherapy to help children struggling with social issues
4. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
5. Dr. Carol Francis Talk Radio - Fifth Year Anniversary Show on "Success Tools, Professional Mental Health & Physical Fitness Advice, Social Justice Issues, Soulful Guests"
6. AED.com Issues Warning to Consumers Concerning AED Scams
7. Stryker Hip Lawsuits Proceed in New Jersey Litigation as Court Issues New Case Orders, Reports Wright & Schulte
8. Medicationdiscountcard.com Issues Advisory: Health Insurance Plans Do Not Cover Many Common Prescription Medications
9. Search Technologies Issues New White Paper Summarizing the Top Ten Applications for the Google Search Appliance
10. Da Vinci Surgical Robot Update: FDA Issues Class 2 Recall of Intuitive Surgical’s da Vinci Robot due to Possibly Inadequate Testing of 30 Units, Notes Parker Waichman LLP
11. AAPCC Issues Statement on Decision of Procter & Gamble to Redesign Tide Pods Packaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Dallas, Texas (PRWEB) September 23, 2014 ... Gunn Finance Tough Mudder team just completed the ... class obstacle course event that helps fund the wounded ... Finance Tough Mudder team member, the ”Tough Mudder is ... military-style obstacle course. Designed and created by British Special ...
(Date:9/23/2014)... University of Cambridge has found that a common characteristic of ... ,signature, in the brain. The results are published today (23 ... The researchers studied 80 adult men with autism: 38 who ... found that language delay was associated with differences in brain ... lobe, insula, ventral basal ganglia, which were all smaller in ...
(Date:9/23/2014)... Published by Nationwide Lifts, the book is designed ... of their mobility in a new way, using equipment that ... lifts are that equipment and can bring mobility and ... elevator business, I’ve seen so many people struggle with ... one with mobility issues,” said Andy Darnley, co-founder and president ...
(Date:9/23/2014)... a popular supplier of wedding dresses and special occasion gowns ... marine ball dresses . Along with this, the firm has ... items; all of them are now provided with deep discounts, ... has won more than 2000 happy customers in the global ... and after-sale services. The company is offering thousands of graceful ...
(Date:9/22/2014)... Recently, BamboofloorChina.com, an outstanding online supplier ... solid bamboo floors . According to the company’s ... at discounted rates, up to 30 percent off. The ... , BamboofloorChina.com is good at making ... are made according to the newest customer feedback. A ...
Breaking Medicine News(10 mins):Health News:Presence or absence of early language delay alters anatomy of the brain in autism 2Health News:Nationwide Lifts, America’s Leader in Home Elevators, Is Proud to Announce the Release of Its First Book, “Stair Lifts: Move Up, Not Out!” 2Health News:Fashionable Marine Ball Dresses Added To BuyTopDress.com’s Collection 2Health News:Cheap Solid Bamboo Floors From Outstanding Online Supplier BamboofloorChina.com 2
... Geneva, Switzerland, Friday, 25 June 2010: Today, world renowned ... latest trends in treatment and cutting edge research in ... hepatocellular carcinoma (HCC) the third most common cause ... of death among patients with liver cirrhosis. ...
... By Ellin Holohan HealthDay Reporter , FRIDAY, ... from chronic migraine headaches feel more rejected, ridiculed, and ... other neurological troubles, a new study contends. And ... victims experience, the Philadelphia researchers say. Lead author ...
... ... Prefer Use of Blood Tests, including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations ... Valencia, CA ... Prevention (CDC) issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, ...
... THURSDAY, June 24 (HealthDay News) -- A new drug, the ... people with type 2 diabetes who are already taking the ... helped patients lose weight, is novel in that it does ... a study appearing in the June 26 issue of ...
... ... Climate Savers Computing Initiative, a non-profit organization dedicated to reducing computer power consumption by 50 ... ... joined the Climate Savers Computing Initiative, a non-profit organization dedicated to reducing computer power consumption ...
... ... with a new technology that the skin care industry has pursued for years: enhanced ... ... new technology that the skin care industry has pursued for years: enhanced absorption. ...
Cached Medicine News:Health News:International liver cancer congress provides possible solutions to reduce significant burden 2Health News:International liver cancer congress provides possible solutions to reduce significant burden 3Health News:For Migraine Sufferers, Stigma Adds to Burden 2Health News:For Migraine Sufferers, Stigma Adds to Burden 3Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 2Health News:TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 3Health News:Drug Helps Tackle Type 2 Diabetes in New Way, Study Says 2Health News:Drug Helps Tackle Type 2 Diabetes in New Way, Study Says 3Health News:Be Green Canada Joins Computing Initiative 2Health News:Be Green Canada Joins Computing Initiative 3Health News:New Anti-Aging Skin Care Line Promotes Penetration 2
(Date:9/22/2014)... Sept. 22, 2014 Children,s National Health ... Sept. 29 at 5 p.m. EDT for its ... in response to continued strong interest from inventors.  ... will be awarded to the winning presentations at ... Symposium hosted by Children,s National in October. For ...
(Date:9/22/2014)... BROOK, N.J. , Sept. 22, 2014 /PRNewswire/ ... antibody therapies to treat infectious disease, today announced ... volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab is ... inhalational anthrax and data from these studies support ... administered intravenously (IV) at the intended therapeutic dose. ...
(Date:9/22/2014)... and SHANGHAI , ... Group (BHG), a global knowledge leader in healthcare ... partnership to support healthcare innovation in ... personal connected health technologies. Continua and BHG announced ... Forum being held this week in ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4
... ULURU Inc. (NYSE Amex: ULU ) ... discuss the third quarter ended September 30, 2010 financial results ... 12, 2010 at 9:00 a.m. Eastern Time. To ... international callers dial (850) 429-1388 (access code 23699#) five to ...
... GAITHERSBURG, Md., Nov. 8, 2010 GenVec, Inc. (Nasdaq: ... ended September 30, 2010.   GenVec reported a net ... ended September 30, 2010 compared to a net loss of $3.6 ... the nine months ended September 30, 2010, GenVec,s net loss was ...
Cached Medicine Technology:ULURU Inc. Announces Conference Call 2GenVec Reports Third Quarter 2010 Financial Results 2GenVec Reports Third Quarter 2010 Financial Results 3GenVec Reports Third Quarter 2010 Financial Results 4GenVec Reports Third Quarter 2010 Financial Results 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: